Holen Sie sich die Stockscreener-App
0.70
2.94%
0.02
Handel nachbörslich:
.71
0.01
+1.43%
Schlusskurs vom Vortag:
$0.68
Offen:
$0.6837
24-Stunden-Volumen:
248.01K
Relative Volume:
1.09
Marktkapitalisierung:
$62.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.15M
KGV:
-0.7692
EPS:
-0.91
Netto-Cashflow:
$-31.63M
1W Leistung:
+0.14%
1M Leistung:
+4.46%
6M Leistung:
-13.15%
1J Leistung:
-70.71%
1-Tages-Spanne:
$0.677
$0.7099
1-Wochen-Bereich:
$0.6755
$0.73
52-Wochen-Spanne:
$0.49
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
Firmenname
Context Therapeutics Inc
Sektor
Branche
Telefon
267-225-7416
Adresse
2001 MARKET STREET, PHILADELPHIA
Vergleichen Sie CNTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.70 | 60.75M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-11-25 | Eingeleitet | D. Boral Capital | Buy |
| 2024-05-16 | Eingeleitet | Piper Sandler | Overweight |
Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten
Applying sector rotation models to Context Therapeutics Inc.Entry Point & Free Verified High Yield Trade Plans - Newser
How Context Therapeutics Inc. stock performs during market volatilityQuarterly Profit Summary & Weekly Top Performers Watchlists - Newser
Best data tools to analyze Context Therapeutics Inc. stockWeekly Volume Report & Free Reliable Trade Execution Plans - Newser
How to read the order book for Context Therapeutics Inc.Earnings Risk Summary & Expert Curated Trade Setup Alerts - Newser
Chart based exit strategy for Context Therapeutics Inc.2025 Institutional Moves & Fast Momentum Stock Entry Tips - Newser
Context Therapeutics Highlights Pipeline Progress, Reports $8.8M Loss in Q2 - MSN
Visual analytics tools that track Context Therapeutics Inc. performanceJuly 2025 Reactions & Long-Term Growth Plans - Newser
Quantitative breakdown of Context Therapeutics Inc. recent moveRate Cut & Real-Time Volume Analysis - Newser
Context Therapeutics Inc. shares fall 1.47% premarket after Anavex Life Sciences reports fiscal 2025 third quarter results. - AInvest
Full technical analysis of Context Therapeutics Inc. stockBuy Signal & Verified Swing Trading Watchlists - Newser
What makes Context Therapeutics Inc. stock price move sharplyEntry Confirmation Using Short-Term Forecasting - Newser
Tools to monitor Context Therapeutics Inc. recovery probabilityAI Intraday Market Movement Prediction Tool - Newser
Context Therapeutics Inc. Stock Support and Resistance Levels You Should KnowAI Generated Buy/Sell Signal Forecast - Newser
William Blair Has Pessimistic Outlook of CNTX Q3 Earnings - Defense World
Analyzing net buyer seller activity in Context Therapeutics Inc.Free Breakout Momentum Picks With Protection - Newser
How sentiment analysis helps forecast Context Therapeutics Inc.Buy Entry Confirmation Based on Technical Analysis - Newser
HC Wainwright Cuts Context Therapeutics (NASDAQ:CNTX) Price Target to $4.00 - Defense World
Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Published on: 2025-08-10 04:36:20 - Newser
Why Context Therapeutics Inc. stock attracts strong analyst attentionFree Real Time Alerts Based on AI Prediction - Newser
Context Therapeutics Inc. shares fall 2.58% intraday as Genmab's epcoritamab development program progresses. - AInvest
Detecting support and resistance levels for Context Therapeutics Inc.Capital Growth Summary Over Five Years - Newser
D. Boral Capital Raises PT to $9 on Context Therapeutics - AInvest
Context Therapeutics: HC Wainwright Downgrades to Buy with $4 PT. - AInvest
Context Therapeutics Q2 net loss widens, cash funds ops into 2027 - MarketScreener
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results - GlobeNewswire
Context Therapeutics Q2 Earnings: Strong $83.5M Cash Position Funds Two Key Cancer Drug Trials - Stock Titan
What technical models suggest about Context Therapeutics Inc.’s comebackShort-Term AI-Based Stock Price Forecast - Newser
Finanzdaten der Context Therapeutics Inc-Aktie (CNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):